Subarachnoid Hemorrhage

Note: the content in these publications is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Novel Dual Lumen Catheter and Filtration Device for Removal of Subarachnoid hemorrhage: First Case Report

Blackburn et al.
Operative Neurosurgery, opy151, https://doi.org/10.1093/ons/opy151 June 5 2017

The amount of subarachnoid blood and the presence of toxic blood breakdown products in the cerebrospinal fluid (CSF) have long been associated with poor outcomes in aneurysmal subarachnoid hemorrhage. The Neurapheresis™ system (Minnetronix Inc, St. Paul, Minnesota) has been developed to filter CSF and remove blood products, and is being investigated for safety and feasibility in the ExtracorPoreal FILtration of subarachnoid hemorrhage via SpinaL CAtheteR (PILLAR) study. We report the first case using this novel device.

Healthcare Economics of Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage in the United States

April 13, 2019 – American Association of Neurological Surgeons, San Diego, CA

Syed M. Adil, BSa; Beiyu Liu, PhDb; Lefko T. Charalambous, BSa; Musa Kiyani, BSa; Robert Gramer, BSa; Christa B. Swisher, MDc; Laura Zitella Verbick, PhDd; Aaron McCabe, PhDd; Beth A. Parente, PA-Ca; Promila Pagadala, PhDa; Shivanand P. Lad MD, PhDa

Background

  • Aneurysmal subarachnoid hemorrhage (aSAH) is a common but devastating condition, with fatality rates of 8-61% in the 1-month after diagnosis.1
  • Hydrocephalus is one of the most common sequelae after aSAH, with its incidence ranging from 15-58.4% in the acute stage (48-72 hours after SAH) to 4.3-37% in the chronic stage (>14 days after SAH).2
  • Management of hydrocephalus involves longer lengths of stay3 and requires placing extraventricular drains, sometimes followed by conversion to ventriculoperitoneal (VP) shunts or endoscopic third ventriculostomy (ETV).
  • Though post-aSAH hydrocephalus is recognized as a common and significant concern, there is scarce literature determining its actual monetary or resource cost.

Objective

  • Quantify the healthcare resource utilization (HCRU) and health economic burden incurred by the US health system due to post-aSAH hydrocephalus.
  • Perform a preliminary analysis regarding the effect of timing of permanent CSF diversion procedure (i.e. VP shunt or ETV) on cost.

Methods (Figure 1)

  • The Truven MarketScan® Research database was used to retrospectively quantify the prevalence and HCRU associated with hydrocephalus in aSAH patients undergoing surgical clipping or endovascular coiling from 2008-2015.
  • Multivariable longitudinal analysis was conducted across 5 years to model the relationship between total annual cost (hospital service cost + medication cost) and hydrocephalus status, controlling for Charlson Comorbidity Index, clipping vs. coiling treatment, sex, and insurance status.
  • Performed a non-multivariable analysis across 2 years comparing HCRU for patients undergoing early (≤21 days after admission) vs. late (22-90 days after admission) CSF diversion procedures.

Results (Figures 2-4)

  • In total, 2374 patients were included; hydrocephalus was diagnosed in 959 (40.4%).
  • In the preliminary HCRU analysis of early vs. late CSF diversion procedures, 306 patients were included.

Conclusion

  • Our study characterizes one of the largest cohorts of aSAH patients in the United States.
  • The healthcare resource utilization due to post-aSAH hydrocephalus in the United States is substantial, resulting in cost increase of nearly $70,000 in first 90 days and $55,000 at 5 years.
  • Future research should further quantify the potential resources that could be saved with early intervention for post-aSAH hydrocephalus.

References

  1. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol.2009;8(7):635-42. doi:10.1016/S1474-4422(09)70126-7.
  2. Xie Z, Hu X, Zan X, Lin S, Li H, You C. Predictors of Shunt-dependent Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage? A Systematic Review and Meta-Analysis. World Neurosurg. 2017;106:844-60 e6. doi:10.1016/j.wneu.2017.06.119.
  3. Rumalla K, Smith KA, Arnold PM, Mittal MK. Subarachnoid Hemorrhage and Readmissions: National Rates, Causes, Risk Factors, and Outcomes in 16,001 Hospitalized Patients. World Neurosurg. 2018;110:e100-e11. doi:10.1016/j.wneu.2017.10.089.5

Author Organization Key

  1. Duke University Medical Center, Department of Neurosurgery
  2. Duke University Medical Center, Department of Biostatistics and Bioinformatics
  3. Duke University Medical Center, Department of Neurology
  4. Minnetronix, Inc, St. Paul, MN, USA

Healthcare Economics of Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage in the United States

March 13, 2019 – Translational Stroke Research, Syed M. Adil, Beiyu Liu, et al

Abstract – Hydrocephalus is one of the most common sequelae after aneurysmal subarachnoid hemorrhage (aSAH), and it is a large contributor to the condition’s high rates of readmission and mortality. Our objective was to quantify the healthcare resource utilization (HCRU) and health economic burden incurred by the US health system due to post-aSAH hydrocephalus. The Truven Health MarketScan® Research database was used to retrospectively quantify the prevalence and HCRU associated with hydrocephalus in aSAH patients undergoing surgical clipping or endovascular coiling from 2008 to 2015. Multivariable longitudinal analysis was conducted to model the relationship between annual cost and hydrocephalus status. In total, 2374 patients were included; hydrocephalus was diagnosed in 959 (40.4%). Those with hydrocephalus had significantly longer initial lengths of stay (median 19.0 days vs. 12.0 days, p < .001) and higher 30-day readmission rates (20.5% vs. 10.4%, p < .001). With other covariates held fixed, in the first 90 days after aSAH diagnosis, the average cost multiplier relative to annual baseline for hydrocephalus patients was 24.60 (95% CI, 20.13 to 30.06; p < .001) whereas for non-hydrocephalus patients, it was 11.52 (95% CI, 9.89 to 13.41; p < .001). The 5-year cumulative median total cost for the hydrocephalus group was $230,282.38 (IQR, 166,023.65 to 318,962.35) versus $174,897.72 (IQR, 110,474.24 to 271,404.80) for those without hydrocephalus. We characterize one of the largest cohorts of post-aSAH hydrocephalus patients in the USA. Importantly, the substantial health economic impact and long-term morbidity and costs from this condition are quantified and reviewed.